CASI Pharmaceuticals (CASI) begins OTCQB trading of ordinary shares as CASIF

Rhea-AI Filing Summary

CASI Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases, reported that its ordinary shares began trading on the OTCQB market under the ticker CASIF on April 14, 2026.

The information in this report is incorporated by reference into the company’s existing shelf registration statements on Form F-3, allowing it to be used in connection with those offerings. The report also reiterates standard forward-looking statement cautions under the U.S. Private Securities Litigation Reform Act of 1995.

Key Figures

OTCQB trading start date: April 14, 2026 Commission File Number: 001-41666 Registration Statements referenced: Form F-3 File Nos. 333-283998, 333-281621 +1 more

4 metrics

OTCQB trading start date April 14, 2026 Date CASI ordinary shares began OTCQB quotation as CASIF

Commission File Number 001-41666 Exchange Act registration reference in Form 6-K

Registration Statements referenced Form F-3 File Nos. 333-283998, 333-281621 Form 6-K information incorporated by reference

Form type Form 6-K Report of foreign private issuer for April 2026

Key Terms

OTCQB, foreign private issuer, Registration Statements on Form F-3, anti-CD38 monoclonal antibody, +2 more

6 terms

OTCQB financial

"the Company’s ordinary shares began to be quoted for trading on the OTCQB under the ticker CASIF"

OTCQB is a tier of the over‑the‑counter (OTC) market where smaller or developing companies list their shares for trading without being on a major stock exchange. Think of it like a well‑kept side street market: companies must meet basic reporting and transparency checks so investors get more information than the lowest OTC tier, but trading is usually less liquid and riskier than on big exchanges. Investors care because OTCQB listings can offer early access to growth stories but come with higher price swings and greater chance of limited resale options.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Registration Statements on Form F-3 regulatory

"incorporated by reference into the Company's Registration Statements on Form F-3"

anti-CD38 monoclonal antibody medical

"developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection"

Private Securities Litigation Reform Act of 1995 regulatory

"made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995"

forward-looking statements regulatory

"This announcement contains forward-looking statements."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2026

Commission File Number  001-41666

CASI PHARMACEUTICALS, INC.

(Translation of registrant’s name into English)

1701-1702, China Central Office Tower 1

No. 81 Jianguo Road, Chaoyang District

Beijing, 100025

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  Form 20-F  x Form 40-F  ¨

INCORPORATION BY REFERENCE

The information included in this Report on Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form F-3 (File No. 333-283998 and No. 333-281621) (including any prospectuses forming a part of such registration statement) and is to be a part thereof from the date on which this Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

CASI Pharmaceuticals Announces Trading on QTCQB

CASI Pharmaceuticals, Inc. (OCTQB: CASIF, the “Company”), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today reported that the Company’s ordinary shares began to be quoted for trading on the OTCQB under the ticker CASIF on April 14, 2026.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CASI Pharmaceuticals, Inc.
	By:	/s/ Wei-Wu He
	Name:	Wei-Wu He
	Title:	Chairman to the Board
Date: April 15, 2026

FAQ

What did CASI (CASI) announce in its April 2026 Form 6-K?

CASI Pharmaceuticals announced that its ordinary shares began trading on the OTCQB market under ticker CASIF on April 14, 2026. The report also incorporates this information by reference into its existing Form F-3 registration statements and includes standard forward-looking statement cautions.

On which market are CASI Pharmaceuticals’ shares now quoted for trading?

CASI Pharmaceuticals’ ordinary shares are quoted for trading on the OTCQB market under the ticker CASIF. The company disclosed this change as of April 14, 2026, through a Form 6-K, providing U.S. investors with information on where its shares can be traded over the counter.

When did CASI Pharmaceuticals shares begin trading on the OTCQB?

CASI Pharmaceuticals stated that its ordinary shares began trading on the OTCQB under ticker CASIF on April 14, 2026. This date marks the start of quotation on that over-the-counter market, as disclosed in the company’s April 2026 Form 6-K filing with the SEC.

What type of company is CASI Pharmaceuticals (CASI)?

CASI Pharmaceuticals is described as a clinical-stage biopharmaceutical company. It is developing CID-103, an anti-CD38 monoclonal antibody intended for patients with organ transplant rejection and autoimmune diseases, according to the business description included in its April 2026 Form 6-K report.

What is CID-103 in CASI Pharmaceuticals’ pipeline?

CID-103 is an anti-CD38 monoclonal antibody being developed by CASI Pharmaceuticals. The company states it is targeting patients with organ transplant rejection and autoimmune diseases, highlighting its focus on immune-related conditions in its clinical-stage biopharmaceutical development activities.

How is this 6-K incorporated into CASI Pharmaceuticals’ SEC registrations?

The company states that the information in this Form 6-K is incorporated by reference into its Form F-3 registration statements, File Nos. 333-283998 and 333-281621. This allows the disclosed OTCQB trading information to become part of those existing shelf registration documents for regulatory and offering purposes.

What forward-looking statement warnings does CASI include in this filing?

CASI notes this announcement contains forward-looking statements made under the safe harbor of the U.S. Private Securities Litigation Reform Act of 1995. It explains such statements involve risks and uncertainties, and refers readers to its SEC filings for further risk information, cautioning against undue reliance on these statements.